Literature DB >> 28353490

Accuracy of Clinician Assessments of Medication Status in the Emergency Setting: A Comparison of Clinician Assessment of Antipsychotic Usage and Plasma Level Determination.

Leonardo V Lopez1, Atef Shaikh, Jonathan Merson, Jessica Greenberg, Raymond F Suckow, John M Kane.   

Abstract

PURPOSE: The present study aimed to assess the level of agreement between clinicians' routine assessments of medication status and plasma levels of commonly prescribed antipsychotic medications in patients presenting to an emergency room with an exacerbation of psychosis.
METHODS: We studied 105 patients presenting to an emergency room and admitted to an inpatient psychiatric unit with a diagnosis of schizophrenia, schizoaffective disorder, bipolar I disorder, or psychotic disorder not otherwise specified and a prior outpatient medication regimen including risperidone, olanzapine, quetiapine, aripiprazole, or paliperidone. Plasma levels of antipsychotics were drawn and sent to a specialty laboratory for testing.
FINDINGS: Of the 97 patients with usable samples, 33 (34%) were found to have therapeutic antipsychotic levels. Of these, 22 were judged by emergency room staff to be taking their medications at the appropriately prescribed doses, whereas 11 were judged not to be taking medication at all. Sixty-four patients were found to have subtherapeutic antipsychotic levels, 31 of whom had been assessed to be taking medication as prescribed. Emergency assessment of medication status predicted therapeutic and nontherapeutic antipsychotic levels at rates of 41.5% and 75%, respectively. Emergency staff assessment was statistically independent from the likelihood of having a therapeutic antipsychotic level. IMPLICATIONS: In patients presenting to emergency rooms with exacerbations of psychosis who are subsequently admitted to an inpatient facility, common assessments of medication status are frequently misleading. Readily available methods for rapidly measuring antipsychotic plasma levels in clinical settings are needed for clinicians to make reliable assessments.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28353490     DOI: 10.1097/JCP.0000000000000697

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  5 in total

1.  What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?

Authors:  Christoph U Correll; Jose M Rubio; John M Kane
Journal:  World Psychiatry       Date:  2018-06       Impact factor: 49.548

2.  Trajectories of adherence to mood stabilizers in patients with bipolar disorder.

Authors:  M Bauer; T Glenn; M Alda; R Bauer; P Grof; W Marsh; S Monteith; R Munoz; N Rasgon; K Sagduyu; P C Whybrow
Journal:  Int J Bipolar Disord       Date:  2019-09-04

3.  Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia.

Authors:  R McCutcheon; K Beck; E D'Ambrosio; J Donocik; C Gobjila; S Jauhar; S Kaar; T Pillinger; T Reis Marques; M Rogdaki; O D Howes
Journal:  Acta Psychiatr Scand       Date:  2017-10-26       Impact factor: 6.392

4.  Psychosis breakthrough on antipsychotic maintenance medication (BAMM): what can we learn?

Authors:  Jose M Rubio; John M Kane
Journal:  NPJ Schizophr       Date:  2017-10-11

5.  Regularity of self-reported daily dosage of mood stabilizers and antipsychotics in patients with bipolar disorder.

Authors:  Maximilian Pilhatsch; Tasha Glenn; Natalie Rasgon; Martin Alda; Kemal Sagduyu; Paul Grof; Rodrigo Munoz; Wendy Marsh; Scott Monteith; Emanuel Severus; Rita Bauer; Philipp Ritter; Peter C Whybrow; Michael Bauer
Journal:  Int J Bipolar Disord       Date:  2018-05-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.